Welcome to our dedicated page for Terns Pharmaceuticals SEC filings (Ticker: TERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a chemistry textbook—especially when Terns Pharmaceuticals links Phase I data, milestone payments and dilution risk in one 300-page document. Investors hunting for pipeline updates or wondering if fresh capital is needed often scroll for hours before finding the answers.
Stock Titan’s AI changes the workflow. Our platform ingests every Terns Pharmaceuticals SEC filing the moment it hits EDGAR and produces plain-English highlights. Need the Terns Pharmaceuticals quarterly earnings report 10-Q filing? We flag trial expenses and cash runway in seconds. Curious about Terns Pharmaceuticals insider trading Form 4 transactions? Get real-time alerts and charts. For deeper dives, our summaries link directly to the page where each disclosure lives, so you can move from headline to source without manual PDF searches.
Here’s what you can explore instantly:
- Terns Pharmaceuticals annual report 10-K simplified—drug pipeline milestones, risk factors and licensing revenue
- Terns Pharmaceuticals Form 4 insider transactions real-time—executive stock transactions and option grants
- Terns Pharmaceuticals proxy statement executive compensation—how trial success metrics drive bonuses
- Terns Pharmaceuticals 8-K material events explained—clinical data releases, financing rounds and collaboration news
- Terns Pharmaceuticals earnings report filing analysis—quarter-over-quarter R&D trends
Whether you’re monitoring the allosteric BCR-ABL program or comparing GLP-1 development costs, understanding Terns Pharmaceuticals SEC documents with AI means spending minutes, not days, on due diligence.
Commodore Capital entities and two individuals report beneficial ownership of 4,650,000 shares of Terns Pharmaceuticals, Inc. common stock, representing 5.3% of the 87,511,048 shares outstanding used as the denominator. The filing on Schedule 13G lists Commodore Capital LP (Delaware), Commodore Capital Master LP (Cayman Islands), and principals Robert Egen Atkinson and Michael Kramarz as filers. The Firm is the investment manager to Commodore Master and the two individuals are managing partners exercising investment discretion. The filing includes a certification that the shares were not acquired to change or influence control of the issuer.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin filed an amendment to Schedule 13G reporting beneficial ownership of 7,495,000 shares of Terns Pharmaceuticals common stock, representing 8.58% of the outstanding shares. The filing states the position is held with shared voting and shared dispositive power and that there is no sole voting or dispositive power. The ownership calculation references 87,337,801 shares outstanding as of May 2, 2025. The filing includes a certification that the shares were not acquired to change or influence control.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
